BioneerCorp
KOSDAQ:064550
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11 710
18 220
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
B
|
BioneerCorp
KOSDAQ:064550
|
323.7B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
390.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.5B USD |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
BioneerCorp
Glance View
BIONEER Corp. engages in the manufacture and sale of biotechnological products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2005-12-29. The firm mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. The company also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The firm operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for BioneerCorp is -2.8%, which is above its 3-year median of -3.2%.
Over the last 3 years, BioneerCorp’s Net Margin has decreased from 10.3% to -2.8%. During this period, it reached a low of -9.3% on Sep 30, 2024 and a high of 10.3% on Sep 30, 2022.